Search Contract Opportunities

RISER Meet and Greet - Phase II   2

ID: 75D30125R73218 • Type: Special Notice

Description

Posted: Dec. 3, 2024, 2:38 p.m. EST

Amendment 2 is to extend the due date for small business interest. The tentative December 11, 2024 date for the meet and greet is no longer valid a new date will be set after Phase II closes on December 16, 2024. More information will be provided once Phase II closes and the Zoom link is provided.

This announcement is not a solicitation. This announcement does not constitute an invitation for bid, request for proposal, or request for quotation and is not to be construed as a commitment by the government. This is for informational purposes only; the government will not reimburse any costs associated with attending the meet and greet.

The CDC is seeking interested large businesses under NAICS 325413 In-Vitro Diagnostic Substance Manufacturing with the current capabilities to provide the services outlined in the attached Performance Work Statement (PWS). The intent of this announcement is to obtain a list of qualified large businesses that would be interested in providing proposals for the attached PWS. The CDC will publish the list of interested large businesses and ask for interested small businesses who could potentially provide services via subcontracts. CDC will then provide a Zoom conference line that will allow businesses to meet to begin to establish a relationship. Do not provide a proposal for this requirement; the CDC is only asking for the information listed below in the announcement at this point.

This announcement is phase one in a three-phase process that will be accomplished by the publication of this announcement and by amending it for future phases. Below is a summary of the phases:

  1. Phase I call for interested large businesses.
  2. Phase II publish information received from large businesses and initiate call for interested small businesses.
  3. Phase III provide the link and finalized dates/times for the virtual meet and greet once the final number of large and small businesses is known.
Posted: Nov. 22, 2024, 7:30 a.m. EST
Posted: Oct. 31, 2024, 7:46 a.m. EDT
Background
The Centers for Disease Control and Prevention (CDC) is responsible for detecting and responding to new and emerging health threats to protect the safety and health of Americans. The CDC collaborates with public health laboratories domestically and internationally to enhance laboratory capability and capacity.

This contract aims to support the CDC's mission by providing high-quality reference pathogens and reagents necessary for surveillance and public health responses, particularly in light of recent health emergencies such as the SARS-CoV-2 pandemic.

Work Details
The contractor shall produce or acquire, characterize, store, and distribute CDC-furnished pathogens and other reagents critical for public health-related laboratory activities. Key tasks include:
1) Producing or acquiring high-quality stocks of reference pathogens, positive controls, detection kits, genomic sequencing components, proficiency panels, etc.;
2) Ensuring availability of these reagents for characterization of circulating and novel pathogens;
3) Developing Standard Operating Procedures (SOPs) for handling pathogens;
4) Maintaining compliance with quality standards such as ISO 9001;
5) Providing technical assistance to state/local public health laboratories;
6) Regularly updating the inventory of reagents based on current surveillance needs;
7) Delivering monthly reports detailing inventory status, QC assays performed, reagent shipments, etc.;
8) Submitting annual technical reports summarizing work performed during each contract year.

Place of Performance
The work will be conducted at contractor facilities that meet biosafety requirements for handling potentially hazardous pathogens.
Show All

Overview

Agency
Centers for Disease Control and Prevention (CDC) [HHS]
Response Deadline
Dec. 16, 2024, 2:00 p.m. EST (original: Nov. 15, 2024, 2:00 p.m. EST) Past Due
Posted
Oct. 31, 2024, 7:46 a.m. EDT (updated: Dec. 3, 2024, 2:38 p.m. EST)
Set Aside
None
NAICS
325413 - In-Vitro Diagnostic Substance Manufacturing
PSC
R499 - Support- Professional: Other
Place of Performance
Atlanta, GA United States
Source
SAM
Current SBA Size Standard
1250 Employees
On 10/31/24 Centers for Disease Control and Prevention issued Special Notice 75D30125R73218 for RISER Meet and Greet - Phase II due 12/16/24.
Primary Contact
Name
Jennifer Gartzke   Profile
Email
jgartzke@cdc.gov
Phone
(404) 498-0020

Documents

Posted documents for Special Notice 75D30125R73218

Question & Answer

Opportunity Lifecycle

Procurement notices related to Special Notice 75D30125R73218

Incumbent or Similar Awards

Potential Bidders and Partners

Awardees that have won contracts similar to Special Notice 75D30125R73218

Similar Active Opportunities

Open contract opportunities similar to Special Notice 75D30125R73218

Additional Details

Source Agency Hierarchy
HEALTH AND HUMAN SERVICES, DEPARTMENT OF > CENTERS FOR DISEASE CONTROL AND PREVENTION > CDC OFFICE OF ACQUISITION SERVICES
FPDS Organization Code
7523-00254
Source Organization Code
100188028
Last Updated
Jan. 15, 2025
Last Updated By
xuy7@cdc.gov
Archive Date
Jan. 15, 2025